Next 10 |
2024-07-18 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 14:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jeffe...
2024-05-23 06:31:51 ET More on Foghorn Therapeutics Foghorn prices $110M mixed-shelf registered direct offering Foghorn Therapeutics appoints Kristian Humer as chief financial officer Read the full article on Seeking Alpha For further details see: Foghorn...
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points Strengthens balance sheet with cash, cash equivalents and short-term investments of $310 million and extends cash runway into 2027 CAMB...
2024-05-20 15:20:29 ET More on Foghorn Therapeutics Foghorn Therapeutics appoints Kristian Humer as chief financial officer Seeking Alpha’s Quant Rating on Foghorn Therapeutics Historical earnings data for Foghorn Therapeutics Financial information for...
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, ...
2024-05-06 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-06 07:58:09 ET More on Foghorn Therapeutics Foghorn Therapeutics appoints Kristian Humer as chief financial officer Foghorn says Eli Lilly picked lung cancer candidate for further studies Seeking Alpha’s Quant Rating on Foghorn Therapeutics His...
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) sele...
News, Short Squeeze, Breakout and More Instantly...
Foghorn Therapeutics Inc. Company Name:
FHTX Stock Symbol:
NASDAQ Market:
Foghorn Therapeutics Inc. Website:
2024-07-18 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 14:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jeffe...